NCT00350025View on ClinicalTrials.gov

Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

41

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

July 31, 2010

Study Completion Date

September 30, 2012

Conditions

Urologic Neoplasm

Interventions

DRUG

Cetuximab

Cetuximab 250mg/m2 IV weekly for each 28 day cycle.

DRUG

Paclitaxel

Paclitaxel 80mg/m2 IV weekly for each 28 day cycle.

Trial Locations (1)

19111

Fox Chase Cancer Center, Philadelphia

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Fox Chase Cancer Center

OTHER